Skip to main content

Table 6 Multivariable Cox proportional hazards regression on mortality in the subsequent period

From: Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

 

Mortalitya

 

Hazard ratio (95 % CI)

P-value*

Race

 White vs. non-white

0.70 (0.39–1.26)

0.231

Lung-function decline group

 Marginal decline vs. stable

2.38 (1.04–5.45)

0.036*

 Significant decline vs. stable

4.42 (2.01–9.71)

<0.001*

BMI

 25–30 vs. < 25

0.53 (0.29–0.97)

0.038*

 ≥30 vs. < 25

0.38 (0.18–0.80)

0.012*

Comorbidities

 Cardiac disorder vs. no cardiac disorder

1.63 (0.94–2.82)

0.080

 Pulmonary hypertension vs. no pulmonary hypertension

2.53 (1.33–4.80)

0.005*

 Emphysema vs. no emphysema

1.49 (0.67–3.35)

0.328

 Gastroesophageal reflux disease vs. no gastroesophageal reflux disease

1.10 (0.64–1.92)

0.725

Smoking status

 History of smoking vs. no history of smoking

1.08 (0.64–1.83)

0.773

Suspected AEx in the concurrent period

 Yes vs. no

2.59 (1.49–4.53)

<0.001*

Use of prednisone and azathioprine in the concurrent period

 Both vs. neither

2.48 (1.19–5.19)

0.016*

 Prednisone only vs. neither

1.41 (0.66–3.01)

0.376

 Azathioprine only vs. neither

1.11 (0.18–7.01)

0.909

Symptoms at initial IPF diagnosis

 Dyspnea vs. no dyspnea

1.29 (0.48–3.48)

0.609

 Weight loss vs. no weight loss

1.95 (1.02–3.73)

0.044*

Physician's main practice setting

 Academic vs. non-academic

0.95 (0.51–1.77)

0.876

GAP index (per unit increase)b

1.19 (0.98–1.44)

0.080

  1. aMultivariable Cox proportional hazard regression was used to estimate the hazard ratio, 95 % confidence interval and p-value, accounting for physician clustering using generalized estimating equations
  2. bThe hazard ratio for the GAP index was estimated for every one point increase in GAP index
  3. *P-values less than 0.05 are indicated with an asterisk (*)